Hepatitis C News and Research

Latest Hepatitis C News and Research

Analysis finds substantially more mutations in the omicron SARS-CoV-2 variant

A University of Florida Health researcher has successfully analyzed the many mutations in the omicron variant of the SARS-CoV-2 virus, a crucial step in better understanding the variant's potential threat and ways to combat it.

9 Dec 2021

Characterization of the baseline SARS-CoV-2 S-reactive B cell repertoire

Researchers from the University Of Amsterdam have identified several oddities in unvaccinated individuals' antibody response to the spike protein.

8 Dec 2021

Interactions between RNA viruses and human RNA-binding proteins

During the virus's attempt to use the host cell to replicate, host proteins interact heavily with the viral genome. Researchers have been investigating these interactions.

8 Dec 2021

Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression

In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease with a high recurrence rate, researchers at the Osaka City University Graduate School of Medicine reported that after receiving cancer treatment, the oral administration of direct-acting antivirals (DAA) reduces the risk of tumor progression following recurrence of the liver disease.

25 Nov 2021

Liver cancer can be recognized by RNA fragments in saliva and blood

RUDN University doctors examined markers of liver cancer and found that the disease can be recognized by RNA fragments in saliva and blood. The results are published in Oncotarget.

23 Nov 2021

WHO’s C-TAP and MPP finalize licensing agreement with CSIC for COVID-19 serological antibody technology

WHO's COVID-19 Technology Access Pool and the Medicines Patent Pool today finalized a licensing agreement with the Spanish National Research Council for a COVID-19 serological antibody technology.

23 Nov 2021

An increase in the half-life of remdesivir for COVID-19 treatment

In this study, researchers analyzed several drug candidates to investigate their efficacy against a broad spectrum of coronaviruses in cell culture studies.

23 Nov 2021

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

A new study describes a new small molecule compound that has shown impressive safety, tolerability, and bioavailability against SARS-CoV-2.

7 Nov 2021

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

The researchers investigated the neutralizing activity of turmeric root extract, curcumin-containing capsules, and pure curcumin against SARS-CoV-2.

1 Nov 2021

Study analyzes the financial burden of chronic hepatitis C on Ontario patients

Ontarians with chronic hepatitis C can lose up to 20 per cent of their overall income managing their condition, a new study has found.

1 Nov 2021

Study focuses on the high hepatitis C rates in pregnant people

Hepatitis C virus (HCV) infection can lead to long-term health problems including liver damage, liver failure, cirrhosis, liver cancer and even death. These outcomes are especially dangerous for pregnant people and their babies.

29 Oct 2021

Chlorophyll catabolite pheophorbide A shows potential against SARS-CoV-2

A new study identifies a potent SARS-CoV-2 antiviral, Pheophorbide a (PheoA), which is a compound derived from the plant Marchantia polymorpha L.

27 Oct 2021

HCV treatment decreases protein activity levels involved in liver cirrhosis, research shows

Researchers at the Medical University of South Carolina report in the Journal of Viral Hepatitis that the activity levels of the proteins involved in liver scarring, or cirrhosis, begin to decrease immediately after treatment for the hepatitis C virus (HCV), suggesting the possibility of early healing.

26 Oct 2021

UQ start-up secures $1.3 million seed investment to develop new treatment for liver disease

A University of Queensland start-up company, developing a potential new treatment for obesity-related liver disease, has secured a seed investment of $1.3 million from IP Group, a UK-based intellectual property business.

19 Oct 2021

The biochemical mechanisms of remdesivir-mediated RNA synthesis inhibition

A new preprint suggests a fruitful approach to develop such drugs based on biochemical and molecular modeling studies of the drug remdesivir.

19 Oct 2021

New high-throughput assay could help development of anti-COVID-19 drugs

In a recent study, researchers develop a new high-throughput assay that allows for rapid screening of potential inhibitors.

13 Oct 2021

Scientists develop an extremely potent siRNA with broad activity against SARS-CoVs

Researchers in Germany have developed a promising approach to suppressing the viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

12 Oct 2021

Study identifies hotspots for opioid overdose and other drug-related disorders

Combining emergency medical services and vital statistics data, a new study led by researchers from Tufts University School of Medicine provides a unique view of the opioid overdose epidemic in an urban area.

12 Oct 2021

Pancreatic cancer clinical trials exclude Black patients based on wide range of eligibility criteria

A simulated pancreatic cancer clinical trial screening process showed that Black patients were significantly more likely than white patients to be excluded from clinical trials for a wide range of eligibility criteria, according to results presented at the virtual 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held October 6-8, 2021.

6 Oct 2021

Needle exchanges are targeted by eco-rooted lawsuits. A new California law will stop that.

For more than 30 years, public health officials and nonprofits in California have provided clean hypodermic needles to people who use them to inject drugs.

6 Oct 2021

Hepatitis C News and Research

Latest Hepatitis C News and Research

Analysis finds substantially more mutations in the omicron SARS-CoV-2 variant

Characterization of the baseline SARS-CoV-2 S-reactive B cell repertoire

Interactions between RNA viruses and human RNA-binding proteins

Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression

Liver cancer can be recognized by RNA fragments in saliva and blood

WHO’s C-TAP and MPP finalize licensing agreement with CSIC for COVID-19 serological antibody technology

An increase in the half-life of remdesivir for COVID-19 treatment

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

Study analyzes the financial burden of chronic hepatitis C on Ontario patients

Study focuses on the high hepatitis C rates in pregnant people

Chlorophyll catabolite pheophorbide A shows potential against SARS-CoV-2

HCV treatment decreases protein activity levels involved in liver cirrhosis, research shows

UQ start-up secures $1.3 million seed investment to develop new treatment for liver disease

The biochemical mechanisms of remdesivir-mediated RNA synthesis inhibition

New high-throughput assay could help development of anti-COVID-19 drugs

Scientists develop an extremely potent siRNA with broad activity against SARS-CoVs

Study identifies hotspots for opioid overdose and other drug-related disorders

Pancreatic cancer clinical trials exclude Black patients based on wide range of eligibility criteria

Needle exchanges are targeted by eco-rooted lawsuits. A new California law will stop that.

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in